^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RPS6KB2 (Ribosomal Protein S6 Kinase B2)

    i
    Other names: RPS6KB2, Ribosomal Protein S6 Kinase B2, STK14B, P70S6Kb, S6Kbeta, S6KB, KLS, 70 KDa Ribosomal Protein S6 Kinase 2, Serine/Threonine-Protein Kinase 14B, Ribosomal Protein S6 Kinase Beta-2, P70 Ribosomal S6 Kinase Beta, S6 Kinase-Related Kinase, P70 S6 Kinase Beta, P70 S6K-Beta, S6K-Beta-2, P70-S6K 2, P70-BETA, P70-Beta, S6K-Beta, P70 S6KB, P70S6K2, S6K2, SRK, Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 2, Ribosomal Protein S6 Kinase, 70kD, Polypeptide 2, Serine/Threonine-Protein Kinase 14 Beta, P70(S6K)-Beta, P70-Beta-1, P70-Beta-2, S6K-Beta2, S6KI(2), S6Kβ
    Associations

    News

    Trials
    3ms
    The long non-coding RNA, CyKILRb, augments oncogenic phenotypes via induction of PIK3R2 and activation of the PI 3 K/AKT axis. (PubMed, bioRxiv)
    PIK3R2 ectopic expression overcame the cellular effects of CyKILRb downregulation, but not PI 3 K or AKT inhibition orienting the signaling pathway from CyKILRb→↑PIK3R2→PI3K→AKT→↓CyKILRa→enhanced oncogenicity. These findings highlight the critical role of CyKILRb in tumorigenesis and define a novel feed-forward regulatory mechanism linked to alternative RNA splicing.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 ) • RPS6KB2 (Ribosomal Protein S6 Kinase B2)
    6ms
    USF1-induced RPS6KB2 activation influences aggressive phenotype in B-cell non-Hodgkin lymphoma. (PubMed, Hum Cell)
    USF1 downregulation inhibited B-NHL progression, which was rescued by RPS6KB2 overexpression. These findings suggest that the USF1-RPS6KB2 axis contributes to B-NHL progression by activating the AKT/HDM2/p53 pathway.
    Journal
    |
    RPS6 (Ribosomal Protein S6) • RPS6KB2 (Ribosomal Protein S6 Kinase B2)
    over1year
    ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export. (PubMed, NPJ Precis Oncol)
    E2F transcription factor 6 (E2F6)-mediated transactivation gave a molecular insight into ALYREF overexpression. Collectively, ALYREF recruits ELAVL1 to collaboratively facilitate m5C recognition and nuclear export of RPS6KB2 and RPTOR transcripts for colorectal tumorigenesis, providing RNA m5C methylation as promising therapeutic targets and prognostic biomarkers for CRC.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • RPS6 (Ribosomal Protein S6) • ELAVL1 (ELAV Like RNA Binding Protein 1) • ALYREF (Aly/REF Export Factor) • RPS6KB2 (Ribosomal Protein S6 Kinase B2) • TFAM (Transcription Factor A, Mitochondrial)
    2years
    Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines. (PubMed, Mol Biol Rep)
    Our research indicates that RPS6KB2 is a prognostic biomarker associated with immune infiltration in cancer that can affect antitumor immunity by increasing secretion of proinflammatory factors, providing a potential drug target for cancer treatment.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability) • BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • RPS6 (Ribosomal Protein S6) • RPS6KB2 (Ribosomal Protein S6 Kinase B2)
    |
    BCL2 expression • BAX expression • PCNA expression
    over2years
    Integrated transcriptome analysis identifies APPL1/RPS6KB2/GALK1 as immune-related metastasis factors in breast cancer. (PubMed, Open Med (Wars))
    Based on the risk score receiver operating characteristic, the three immune-related prognosis factors could be potential biomarkers of BC metastasis. In conclusion, APPL1, RPS6KB2, and GALK1 may play a pivotal role as potential biomarkers for prediction of BC metastasis.
    Journal
    |
    RPS6KB2 (Ribosomal Protein S6 Kinase B2)